Shots:

• NextCure to get $25M upfront plus milestones & royalty payments in addition to $15M equity investments. NextCure & Lilly will hold equal rights to exclusively license the Abs
• The focus of the agreement is to develop novel immunotherapies using NextCure’s FIND-IO technology in the fields of oncology
• FIND-IO platform has ability to identify cell surface molecular interactions while converting them into disease modifying immunotherapies

Ref: Eli Lilly | Image: Eli Lilly